...
首页> 外文期刊>Neural regeneration research >The intra-neuroendoscopic technique: A new method for rapid removal of acute severe intraventricular hematoma
【24h】

The intra-neuroendoscopic technique: A new method for rapid removal of acute severe intraventricular hematoma

机译:神经内镜技术:一种快速清除急性严重脑室内血肿的新方法

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The mortality rate of acute severe intraventricular hematoma is extremely high, and the rate of disability in survivors is high. Intraventricular hematoma has always been a difficult problem for clinical treatment. Although minimally invasive endoscopic hematoma evacuation is widely used to treat this disease, the technique still has room for improvement. Equipment for the intra-neuroendoscopic technique (INET) consists of two of our patented inventions: a transparent sheath (Patent No. ZL 200820046232.0) and a hematoma aspirator (Patent No. ZL 201520248717.8). This study explored the safety and efficacy of INET by comparing it with extraventricular drainage in combination with urokinase thrombolytic therapy. This trial recruited 65 patients with severe intraventricular hemorrhage, including 35 (19 men and 16 women, aged 53.2 ± 8.7 years) in the INET group and 30 (17 men and 13 women, aged 51.5 ± 7.9 years) in the control group (extraventricular drainage plus urokinase thrombolytic therapy). Our results showed that compared with the control group, the INET group exhibited lower intraventricular hemorrhage volumes, shorter intensive care-unit monitoring and ventricular drainage-tube placement times, and fewer incidences of intracranial infection, secondary bleeding, and mortality. Thus, the prognosis of survivors had improved remarkably. These findings indicate that INET is a safe and efficient new method for treating severe intraventricular hematoma. This trial was registered with ClinicalTrials.gov (NCT02515903).
机译:急性严重脑室内血肿的死亡率极高,幸存者的残疾率也很高。脑室内血肿一直是临床治疗中的难题。尽管微创内窥镜血肿清除术已广泛用于治疗该疾病,但该技术仍有改进的空间。神经内窥镜内窥镜技术(INET)的设备由我们的两项专利发明组成:透明护套(专利号ZL 200820046232.0)和血肿抽吸器(专利号ZL 201520248717.8)。这项研究通过将INET与脑室引流结合尿激酶溶栓治疗相比较,探索了INET的安全性和有效性。该试验招募了65例严重的脑室内出血患者,其中INET组35例(男19例,女16例,年龄53.2±8.7岁),对照组(脑室内)30例(男17例,女13例,年龄51.5±7.9岁)。引流加尿激酶溶栓治疗)。我们的结果表明,与对照组相比,INET组的脑室内出血量更低,重症监护病房监测和心室引流管放置时间更短,颅内感染,继发性出血和死亡率的发生率更低。因此,幸存者的预后明显改善。这些发现表明,INET是一种治疗严重脑室内血肿的安全有效的新方法。该试验已在ClinicalTrials.gov(NCT02515903)上注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号